Beyond anti-CD19 CARTs: the future of CAR T-cells depends on the convergence of technologies

STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see the first adoptive cell therapy products approved in the year 2017. Novartis, Kite Pharma and Juno Therapeutics are in a head-to-head race to be first on the market with anti-CD19 chimeric antigen receptor (CAR) T-cells. However, the success story with CD19 CAR T-cells is not as easily repeated with CAR T-cells directed against other targets in hematologic malignancies and - even more - in solid tumors. Limitations by lack of target specificity resulting in on-target, off-tumor toxicity, is one of the major hurdles associated with insufficient activity of current CAR constructs.

As a consequence, the limitations are adressed by a multitude of measures. Gene editing capabilities appears as a key technology not only to generate allogeneic CAR T-cells from donor cells or renewable, pluripotent stem cells, but also to bring CAR design and engineering to a new level of multiplex editing. Knock-out of auto-antigens or immune checkpoints, but also incorporation of on- and off switches for controlling of T-cell activity and enhance potency are some of the features enableb by genome editing of T-cells.

In a new report released by La Merie Publishing, the competitive landscape of CAR T-Cell stakeholders, technologies, pipelines, financing and deals is described and analyzed.

This report „TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs“ describes and analyzes the status of the adoptive cell therapy industry as of August 2016. The report covers autologous and allogeneic engineered chimeric antigen receptor (CAR) and T-cell receptor (TCR) T-cell therapy candidates as well as natural killer (NK) cell and CAR engineered NK cells in research and development by biopharmaceutical companies. Cytotoxic lymphocytes (CTLs), donor lymphocyte infusions (TILs) and tumor infiltrating lymphocytes (TILs) complement the spectrum of the report.

About La Merie

La Merie Publishing is a Business Intelligence enterprise fully dedicated to provide high quality R&D information to the biopharmaceutical industry. La Merie offers individual consultancy services and publishes reports and periodicals. For more information visit and, the Biologics News Center and Online Store of La Merie Publishing.

SOURCE: La Merie Publishing

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up